Table 1.
Demographic and Baseline Characteristics
| Characteristics | COVIG Group (n = 10) |
IVIG Group (n = 8) |
|---|---|---|
| Age (years)—median (IQR) | 48 (27–61) | 63 (41–72) |
| Male gender—no. (%) | 6 (60) | 4 (50) |
| BMIa (kg/m2)—median (IQR) | 26 (24–32) | 29 (24–33) |
| Charlson comorbidity index, median (IQR) | 2 (2–4) | 5 (2–7) |
| Cause of Immunocompromised State, No. (%) | … | … |
| ȃImmunosuppression for solid organ transplant | 4 (40) | 5 (63) |
| ȃRecent use of anti-B-cell therapy for malignancy | 3 (30) | 3 (38) |
| ȃImmunosuppression for autoimmune disease | 1 (10) | 0 (0) |
| ȃCongenital hypogammaglobulinemia | 1 (10) | 0 (0) |
| ȃAcquired hypogammaglobulinemia | 1 (10) | 0 (0) |
| Prior Vaccination Against SARS-CoV-2 | … | … |
| ȃOne or more | 5 (50) | 8 (100) |
| ȃFull scheduleb | 5 (50) | 6 (75) |
| Number of days since symptom onset, median (IQR) | 10 (8–22) | 8 (6–26) |
| Number of days since admission to hospital, median (IQR) | 2 (1–4) | 1 (1–2) |
| Corticosteroid therapy for COVID-19 at baselinec, no. (%) | 10 (100) | 4 (50) |
| Tocilizumab therapy for COVID-19 at baseline, no. (%) | 1 (10) | 0 (0) |
| Respiratory Support | … | … |
| ȃNo oxygen supplementation, no. (%) | 1 (10) | 4 (50) |
| ȃSimple oxygen supplementationd, no. (%) | 9 (90) | 4 (50) |
| ȃRequired oxygen dose (L/min), median (IQR) | 3 (1–8) | 1 (0–4) |
| SARS-CoV-2 Variant | … | … |
| ȃWild-type, no. (%) | 1 (10) | 1 (13) |
| ȃAlpha, no. (%) | 5 (50) | 5 (63) |
| ȃUnknown, no. (%) | 4 (40) | 2 (25) |
| Presence SARS-CoV-2 IgG, no. (%) | 2 (20) | 0 (0) |
| B cell count (per µL)e, median (IQR) | 12 (0–144) | 20 (0–40) |
| CD4 T cell counte | 111 (65–257) | 147 (53–298) |
| CD8 T cell counte | 140 (71–227) | 180 (140–245) |
| NK cell counte | 60 (41–90) | 90 (50–176) |
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019;
COVIG, antisevere acute respiratory syndrome coronavirus 2 hyperimmune intravenous globulin; IgG, immunoglobulin G; IQR, interquartile range; IVIG, intravenous immunoglobulin; NK, natural killer; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
BMI was not available for 1 patient in both groups.
Patient was considered as fully vaccinated 7 days after a second vaccination with Moderna or BioNTech/Pfizer COVID-19 vaccine, 14 days after Janssen COVID-19 vaccine, or after 1 Moderna or BioNTech/Pfizer COVID-19 vaccine in combination with prior SARS-CoV-2 infection.
All patients that required supplemental oxygen received corticosteroid therapy per standard of care.
Oxygen supplementation via nasal cannula.
Counts were not available for 3 patients in the COVIG group.